Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema

OBJECTIVE: To determine the safety of using angiotensin II receptor blockers in patients who have experienced angioedema following treatment with angiotensin-converting enzyme (ACE) inhibitors. DATA SOURCES: Clinical literature identified through MEDLINE (January 1966-August 1999). Key search terms included angioneurotic edema, angiotensin-converting enzyme inhibitors, receptors-angiotensin, and losartan. DATA SYNTHESIS: ACE inhibitor-induced angioedema occurs with an incidence of 0.1-0.5%. Alternative therapy is necessary for patients who experience this potentially life-threatening adverse effect. Since angiotensin II receptor blockers do not increase concentrations of bradykinin, the proposed mechanism of ACE inhibitor-induced angioedema, they were presumed to be safe alternatives. Recent case reports, however, document angioedema following therapy with angiotensin II receptor blockers; 32% of the reported patients experienced a prior episode of angioedema attributed to ACE inhibitor therapy. CONCLUSIONS: Until the exact cause of both ACE inhibitor- and angiotensin II receptor blocker-induced angioedema is determined, angiotensin II receptor blockers should be used with extreme caution in patients with a prior history of angioedema.

This article has been cited by other articles:

				D. Nykamp and E. E Winter Olmesartan Medoxomil-Induced Angioedema Ann. Pharmacother., March 1, 2007; 41(3): 518 - 520. [Abstract] [Full Text] [PDF]

				Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143. [Full Text] [PDF]

				S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society Circulation, September 20, 2005; 112(12): 1825 - 1852. [Full Text] [PDF]

				L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]

				H. H. Ramadan and A. A. El Solh An Update on Otolaryngology in Critical Care Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1273 - 1277. [Full Text] [PDF]

				M. Cicardi, L. C. Zingale, L. Bergamaschini, and A. Agostoni Angioedema Associated With Angiotensin-Converting Enzyme Inhibitor Use: Outcome After Switching to a Different Treatment Arch Intern Med, April 26, 2004; 164(8): 910 - 913. [Abstract] [Full Text] [PDF]

				M. J. Flais Literature Reports of Angiotensin Receptor Antagonist-Induced Angioedema in Patients With a History of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema Arch Intern Med, June 23, 2003; 163(12): 1488 - 1488. [Full Text] [PDF]

				J. A. MacLean and P. J. Hannaway Angioedema and AT1 Receptor Blockers: Proceed With Caution Arch Intern Med, June 23, 2003; 163(12): 1488 - 1489. [Full Text] [PDF]

				D. B. Pitts, A. Goto, and A. S. Levey Nondiabetic Kidney Disease N. Engl. J. Med., February 20, 2003; 348(8): 762 - 763. [Full Text] [PDF]

				D. A Sica and T. W. Gehr Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 247 - 254. [Abstract] [PDF]

				R. D. Brumley, S. de Denus, S. A. Spinler, A. F. Jerant, and L. W. Stevenson Treatment of Congestive Heart Failure JAMA, May 1, 2002; 287(17): 2209 - 2210. [Full Text] [PDF]

				R. Corti, J. C. Burnett Jr, J. L. Rouleau, F. Ruschitzka, and T. F. Luscher Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? Circulation, October 9, 2001; 104(15): 1856 - 1862. [Abstract] [Full Text] [PDF]